holybun的个人主页 - 老虎社区

holybun

holybun

暂无个人介绍

IP属地：未知

2关注

1粉丝

0主题

0勋章

2021-12-22

I think he needs a new cfo, like like there's no financial planning within the company

抱歉，原内容已删除

2021-12-21

Wow, just wow

Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote>

2021-12-16

very nice

@MillionaireTiger:Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion

2021-12-15

I like what I'm seeing

Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100142878992660","uuid":"4100142878992660","gmtCreate":1637039811799,"gmtModify":1640286010040,"name":"holybun","pinyin":"holybun","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.22","exceedPercentage":"93.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.17","exceedPercentage":"93.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691187998,"gmtCreate":1640150149936,"gmtModify":1640150150023,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I think he needs a new cfo, like like there's no financial planning within the company","listText":"I think he needs a new cfo, like like there's no financial planning within the company","text":"I think he needs a new cfo, like like there's no financial planning within the company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691187998","repostId":"2193167797","repostType":4,"isVote":1,"tweetType":1,"viewCount":1208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693778284,"gmtCreate":1640090951437,"gmtModify":1640090951437,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"Wow, just wow","listText":"Wow, just wow","text":"Wow, just wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693778284","repostId":"1148289841","repostType":4,"repost":{"id":"1148289841","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640085374,"share":"https://www.laohu8.com/m/news/1148289841?lang=zh_CN&edition=full","pubTime":"2021-12-21 19:16","market":"us","language":"en","title":"Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148289841","media":"Benzinga","summary":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalm","content":"<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p><p><blockquote><b>阿尔代拉治疗公司</b>报告了reproxalap滴眼液治疗干眼症的3期TRANQUILITY试验的顶线数据。</blockquote></p><p> <ul>  <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>  <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>  <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>  <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>  <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>  <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>  <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>  <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li> </ul> <img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该试验未能达到眼睛发红的主要终点，但在次要终点Schirmer检验的干眼症体征方面确实达到了统计学意义。</li><li>对超过10 mm的Schirmer试验应答者的事后评估也达到了统计学显著性。</li><li>即将进行的3期TRANQUILITY-2试验的主要终点已被修改，如果Schirmer检验或眼部发红显示出统计学显著性，则达到终点。</li><li>此外，TRANQUILITY-2的目标入组已从300名患者增加到最多400名患者。该公司预计营收将于2022年中期公布。</li><li>公司拟于2022年年中提交干眼症适应症的上市申请。</li><li>过敏性结膜炎（另一个拟定适应症）的申请预计将在提交干眼症后和完成FDA要求的额外过敏原室试验后进行。</li><li>未观察到安全性信号，reproxalap耐受性良好；无治疗相关停药或中度或重度不良事件。</li><li><b>价格走势：</b>周二最后一次盘前交易中，ALDX股价下跌38.29%，至4.4美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-21 19:16</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p><p><blockquote><b>阿尔代拉治疗公司</b>报告了reproxalap滴眼液治疗干眼症的3期TRANQUILITY试验的顶线数据。</blockquote></p><p> <ul>  <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>  <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>  <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>  <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>  <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>  <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>  <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>  <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li> </ul> <img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该试验未能达到眼睛发红的主要终点，但在次要终点Schirmer检验的干眼症体征方面确实达到了统计学意义。</li><li>对超过10 mm的Schirmer试验应答者的事后评估也达到了统计学显著性。</li><li>即将进行的3期TRANQUILITY-2试验的主要终点已被修改，如果Schirmer检验或眼部发红显示出统计学显著性，则达到终点。</li><li>此外，TRANQUILITY-2的目标入组已从300名患者增加到最多400名患者。该公司预计营收将于2022年中期公布。</li><li>公司拟于2022年年中提交干眼症适应症的上市申请。</li><li>过敏性结膜炎（另一个拟定适应症）的申请预计将在提交干眼症后和完成FDA要求的额外过敏原室试验后进行。</li><li>未观察到安全性信号，reproxalap耐受性良好；无治疗相关停药或中度或重度不良事件。</li><li><b>价格走势：</b>周二最后一次盘前交易中，ALDX股价下跌38.29%，至4.4美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148289841","content_text":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.\n\nThe trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.\nStatistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.\nThe primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.\nIn addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.\nThe company intends to file the marketing application for dry eye disease indication in mid-2022.\nApplication for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.\nNo safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.\nPrice Action: ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.","news_type":1,"symbols_score_info":{"ALDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690959006,"gmtCreate":1639624289105,"gmtModify":1639624315784,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"very nice","listText":"very nice","text":"very nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690959006","repostId":"607944827","repostType":1,"repost":{"id":607944827,"gmtCreate":1639481361363,"gmtModify":1639504322704,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/8901a3026957857b6996ae953d595bee","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667618821228","idStr":"3527667618821228"},"themes":[],"title":"Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion","htmlText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","listText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","text":"Hey Tigers! Do you notice Pfizer's new play? Pfizer announced its acquisition of Arena Pharmaceuticals today in a $6.7 billion deal for the company’s research on inflammatory conditions affecting the stomach and intestine. Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly doubled yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607944827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607232042,"gmtCreate":1639543357033,"gmtModify":1639543357033,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I like what I'm seeing","listText":"I like what I'm seeing","text":"I like what I'm seeing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607232042","repostId":"1156446659","repostType":4,"repost":{"id":"1156446659","kind":"news","pubTimestamp":1639540344,"share":"https://www.laohu8.com/m/news/1156446659?lang=zh_CN&edition=full","pubTime":"2021-12-15 11:52","market":"us","language":"en","title":"Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156446659","media":"Business Insider","summary":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Frid","content":"<p><ul>  <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>  <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>  <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p><p><blockquote><ul><li><b>周五，Berkshire Hathaway持有的苹果8.87亿股股票价值增至1,590亿美元。</b></li><li><b>这使得这些股份价值占伯克希尔整个股票投资组合的一半，占其6490亿美元市值的近25%。</b></li><li><b>Warren Buffett于2016年开始建立Berkshire在苹果的头寸，并一直持续到2018年年中。</b></li></ul><p class=\"t-img-caption\"><span>斯科特·摩根/路透社</span></p></blockquote></p><p> Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p><p><blockquote>沃伦·巴菲特以集中投资创造世代财富而闻名，伯克希尔·哈撒韦公司在苹果的股份就是这种投资实践的最好例子。</blockquote></p><p> Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p><p><blockquote>周五，伯克希尔持有这家iPhone制造商的8.871亿股股票价值飙升至创纪录的1,590亿美元，较其原始成本基础约360亿美元增长了342%。根据伯克希尔第三季度13F文件的数据，这意味着苹果目前的价值超过了伯克希尔2930亿美元股票投资组合的一半。</blockquote></p><p> And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p><p><blockquote>假设伯克希尔哈撒韦公司自9月30日以来没有削减其在苹果的头寸，那么这些股权目前约占伯克希尔哈撒韦公司6490亿美元市值的四分之一。</blockquote></p><p> What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p><p><blockquote>巴菲特对苹果的专注也值得注意，因为它并不像巴菲特管理的大多数成功投资那样需要几十年的时间才能实现复利。相反，从Berkshire开始增持苹果股份到现在才五年。</blockquote></p><p> The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p><p><blockquote>该集团于2016年首次购买了苹果股票，并一直购买到2018年中期，在对2020年4比1的股票分割进行调整后，该持仓量突破10亿股。自最初增持苹果股份以来，巴菲特已将其持有的股份削减了约12%。</blockquote></p><p> Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p><p><blockquote>根据Bespoke的分析，除非自最近一次13F备案以来发生任何变化，否则Berkshire的股票投资组合本季度迄今将上涨13.9%。这一涨幅很大程度上是由苹果本季度迄今超过20%的涨幅推动的。</blockquote></p><p> Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p><p><blockquote>今年迄今为止，苹果股价上涨了31%，而Berkshire Hathaway的回报率为26%。周一，苹果股价距离触及3万亿美元估值不到1.00美元。</blockquote></p><p> Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p><p><blockquote>继苹果之后，伯克希尔最大的三个持仓是美国银行、美国运通和可口可乐，它们合计占股票投资组合价值的30%。伯克希尔仍坐拥约1500亿美元现金尚未投入使用。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Insider</strong><span class=\"h-time small\">2021-12-15 11:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>  <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>  <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p><p><blockquote><ul><li><b>周五，Berkshire Hathaway持有的苹果8.87亿股股票价值增至1,590亿美元。</b></li><li><b>这使得这些股份价值占伯克希尔整个股票投资组合的一半，占其6490亿美元市值的近25%。</b></li><li><b>Warren Buffett于2016年开始建立Berkshire在苹果的头寸，并一直持续到2018年年中。</b></li></ul><p class=\"t-img-caption\"><span>斯科特·摩根/路透社</span></p></blockquote></p><p> Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p><p><blockquote>沃伦·巴菲特以集中投资创造世代财富而闻名，伯克希尔·哈撒韦公司在苹果的股份就是这种投资实践的最好例子。</blockquote></p><p> Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p><p><blockquote>周五，伯克希尔持有这家iPhone制造商的8.871亿股股票价值飙升至创纪录的1,590亿美元，较其原始成本基础约360亿美元增长了342%。根据伯克希尔第三季度13F文件的数据，这意味着苹果目前的价值超过了伯克希尔2930亿美元股票投资组合的一半。</blockquote></p><p> And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p><p><blockquote>假设伯克希尔哈撒韦公司自9月30日以来没有削减其在苹果的头寸，那么这些股权目前约占伯克希尔哈撒韦公司6490亿美元市值的四分之一。</blockquote></p><p> What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p><p><blockquote>巴菲特对苹果的专注也值得注意，因为它并不像巴菲特管理的大多数成功投资那样需要几十年的时间才能实现复利。相反，从Berkshire开始增持苹果股份到现在才五年。</blockquote></p><p> The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p><p><blockquote>该集团于2016年首次购买了苹果股票，并一直购买到2018年中期，在对2020年4比1的股票分割进行调整后，该持仓量突破10亿股。自最初增持苹果股份以来，巴菲特已将其持有的股份削减了约12%。</blockquote></p><p> Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p><p><blockquote>根据Bespoke的分析，除非自最近一次13F备案以来发生任何变化，否则Berkshire的股票投资组合本季度迄今将上涨13.9%。这一涨幅很大程度上是由苹果本季度迄今超过20%的涨幅推动的。</blockquote></p><p> Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p><p><blockquote>今年迄今为止，苹果股价上涨了31%，而Berkshire Hathaway的回报率为26%。周一，苹果股价距离触及3万亿美元估值不到1.00美元。</blockquote></p><p> Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p><p><blockquote>继苹果之后，伯克希尔最大的三个持仓是美国银行、美国运通和可口可乐，它们合计占股票投资组合价值的30%。伯克希尔仍坐拥约1500亿美元现金尚未投入使用。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12\">Business Insider</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156446659","content_text":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.\nWarren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.\n\nSCOTT MORGAN/REUTERS\nWarren Buffett is known for concentrating his investments to build generational wealth, and Berkshire Hathaway's stake in Apple is no better example of that investment practice.\nBerkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.\nAnd assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.\nWhat also makes Buffett's concentration in Apple notable is that it didn't take decades to compound like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.\nThe conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has trimmed Berkshire's position in Apple by about 12% since initially building the stake.\nBarring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.\nYear-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than $1.00 away from hitting a $3 trillion valuation on Monday.\nBerkshire's three largest positions after Apple are Bank of America,American Express, and Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.","news_type":1,"symbols_score_info":{"AAPL":0.9,"BRK.B":0.9,"BRK.A":0.9}},"isVote":1,"tweetType":1,"viewCount":3154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":607232042,"gmtCreate":1639543357033,"gmtModify":1639543357033,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I like what I'm seeing","listText":"I like what I'm seeing","text":"I like what I'm seeing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607232042","repostId":"1156446659","repostType":4,"repost":{"id":"1156446659","kind":"news","pubTimestamp":1639540344,"share":"https://www.laohu8.com/m/news/1156446659?lang=zh_CN&edition=full","pubTime":"2021-12-15 11:52","market":"us","language":"en","title":"Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156446659","media":"Business Insider","summary":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Frid","content":"<p><ul>  <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>  <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>  <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p><p><blockquote><ul><li><b>周五，Berkshire Hathaway持有的苹果8.87亿股股票价值增至1,590亿美元。</b></li><li><b>这使得这些股份价值占伯克希尔整个股票投资组合的一半，占其6490亿美元市值的近25%。</b></li><li><b>Warren Buffett于2016年开始建立Berkshire在苹果的头寸，并一直持续到2018年年中。</b></li></ul><p class=\"t-img-caption\"><span>斯科特·摩根/路透社</span></p></blockquote></p><p> Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p><p><blockquote>沃伦·巴菲特以集中投资创造世代财富而闻名，伯克希尔·哈撒韦公司在苹果的股份就是这种投资实践的最好例子。</blockquote></p><p> Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p><p><blockquote>周五，伯克希尔持有这家iPhone制造商的8.871亿股股票价值飙升至创纪录的1,590亿美元，较其原始成本基础约360亿美元增长了342%。根据伯克希尔第三季度13F文件的数据，这意味着苹果目前的价值超过了伯克希尔2930亿美元股票投资组合的一半。</blockquote></p><p> And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p><p><blockquote>假设伯克希尔哈撒韦公司自9月30日以来没有削减其在苹果的头寸，那么这些股权目前约占伯克希尔哈撒韦公司6490亿美元市值的四分之一。</blockquote></p><p> What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p><p><blockquote>巴菲特对苹果的专注也值得注意，因为它并不像巴菲特管理的大多数成功投资那样需要几十年的时间才能实现复利。相反，从Berkshire开始增持苹果股份到现在才五年。</blockquote></p><p> The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p><p><blockquote>该集团于2016年首次购买了苹果股票，并一直购买到2018年中期，在对2020年4比1的股票分割进行调整后，该持仓量突破10亿股。自最初增持苹果股份以来，巴菲特已将其持有的股份削减了约12%。</blockquote></p><p> Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p><p><blockquote>根据Bespoke的分析，除非自最近一次13F备案以来发生任何变化，否则Berkshire的股票投资组合本季度迄今将上涨13.9%。这一涨幅很大程度上是由苹果本季度迄今超过20%的涨幅推动的。</blockquote></p><p> Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p><p><blockquote>今年迄今为止，苹果股价上涨了31%，而Berkshire Hathaway的回报率为26%。周一，苹果股价距离触及3万亿美元估值不到1.00美元。</blockquote></p><p> Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p><p><blockquote>继苹果之后，伯克希尔最大的三个持仓是美国银行、美国运通和可口可乐，它们合计占股票投资组合价值的30%。伯克希尔仍坐拥约1500亿美元现金尚未投入使用。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Warren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWarren Buffett has grown Berkshire Hathaway's Apple stake to 50% of its entire equity portfolio and nearly a quarter of its $649 billion market cap<blockquote>Warren Buffett已将Berkshire Hathaway持有的苹果股份增至其全部股票投资组合的50%，占其6490亿美元市值的近四分之一</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Insider</strong><span class=\"h-time small\">2021-12-15 11:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li><b>Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.</b></li>  <li><b>That makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.</b></li>  <li><b>Warren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.</b></li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4348b5dc216a2be5e154d22e356336b9\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"><span>SCOTT MORGAN/REUTERS</span></p><p><blockquote><ul><li><b>周五，Berkshire Hathaway持有的苹果8.87亿股股票价值增至1,590亿美元。</b></li><li><b>这使得这些股份价值占伯克希尔整个股票投资组合的一半，占其6490亿美元市值的近25%。</b></li><li><b>Warren Buffett于2016年开始建立Berkshire在苹果的头寸，并一直持续到2018年年中。</b></li></ul><p class=\"t-img-caption\"><span>斯科特·摩根/路透社</span></p></blockquote></p><p> Warren Buffett is known for concentrating his investments to build generational wealth, and&nbsp;Berkshire Hathaway's&nbsp;stake in&nbsp;Apple&nbsp;is no better example of that investment practice.</p><p><blockquote>沃伦·巴菲特以集中投资创造世代财富而闻名，伯克希尔·哈撒韦公司在苹果的股份就是这种投资实践的最好例子。</blockquote></p><p> Berkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its&nbsp;original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.</p><p><blockquote>周五，伯克希尔持有这家iPhone制造商的8.871亿股股票价值飙升至创纪录的1,590亿美元，较其原始成本基础约360亿美元增长了342%。根据伯克希尔第三季度13F文件的数据，这意味着苹果目前的价值超过了伯克希尔2930亿美元股票投资组合的一半。</blockquote></p><p> And assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.</p><p><blockquote>假设伯克希尔哈撒韦公司自9月30日以来没有削减其在苹果的头寸，那么这些股权目前约占伯克希尔哈撒韦公司6490亿美元市值的四分之一。</blockquote></p><p> What also makes Buffett's concentration in Apple notable is that it didn't take&nbsp;decades to compound&nbsp;like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.</p><p><blockquote>巴菲特对苹果的专注也值得注意，因为它并不像巴菲特管理的大多数成功投资那样需要几十年的时间才能实现复利。相反，从Berkshire开始增持苹果股份到现在才五年。</blockquote></p><p> The conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has&nbsp;trimmed Berkshire's position in Apple&nbsp;by about 12% since initially building the stake.</p><p><blockquote>该集团于2016年首次购买了苹果股票，并一直购买到2018年中期，在对2020年4比1的股票分割进行调整后，该持仓量突破10亿股。自最初增持苹果股份以来，巴菲特已将其持有的股份削减了约12%。</blockquote></p><p> Barring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to&nbsp;an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.</p><p><blockquote>根据Bespoke的分析，除非自最近一次13F备案以来发生任何变化，否则Berkshire的股票投资组合本季度迄今将上涨13.9%。这一涨幅很大程度上是由苹果本季度迄今超过20%的涨幅推动的。</blockquote></p><p> Year-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than&nbsp;$1.00 away from hitting a $3 trillion valuation on Monday.</p><p><blockquote>今年迄今为止，苹果股价上涨了31%，而Berkshire Hathaway的回报率为26%。周一，苹果股价距离触及3万亿美元估值不到1.00美元。</blockquote></p><p> Berkshire's three largest positions after Apple are&nbsp;Bank of America,American Express, and&nbsp;Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.</p><p><blockquote>继苹果之后，伯克希尔最大的三个持仓是美国银行、美国运通和可口可乐，它们合计占股票投资组合价值的30%。伯克希尔仍坐拥约1500亿美元现金尚未投入使用。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12\">Business Insider</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://markets.businessinsider.com/news/stocks/warren-buffett-apple-stake-half-berkshire-hathaway-equity-portfolio-concentration-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156446659","content_text":"Berkshire Hathaway's Apple holdings of 887 million shares swelled to a value of $159 billion on Friday.\nThat makes the stake worth half of Berkshire's entire equity portfolio, and almost 25% of its $649 billion market capitalization.\nWarren Buffett started to build Berkshire's position in Apple in 2016 and added to it up until mid-2018.\n\nSCOTT MORGAN/REUTERS\nWarren Buffett is known for concentrating his investments to build generational wealth, and Berkshire Hathaway's stake in Apple is no better example of that investment practice.\nBerkshire's 887.1 million shares in the iPhone maker swelled to a record value of $159 billion on Friday, a 342% increase from its original cost basis of about $36 billion.That means Apple is now worth more than half of Berkshire's $293 billion equity portfolio, based on data from its third-quarter 13F filing.\nAnd assuming Berkshire hasn't trimmed its Apple position since September 30, the equity stake now represents about a quarter of Berkshire Hathaway's $649 billion market capitalization.\nWhat also makes Buffett's concentration in Apple notable is that it didn't take decades to compound like most successful investments managed by Buffett. Instead, it's only been five years since Berkshire began to build its stake in Apple.\nThe conglomerate first purchased Apple shares in 2016 and continued buying them until mid-2018, when the position topped 1 billion shares after adjusting for a 4-for-1 stock split in 2020. Buffett has trimmed Berkshire's position in Apple by about 12% since initially building the stake.\nBarring any changes since the most recent 13F filing, Berkshire's stock portfolio would be up 13.9% quarter-to-date, according to an analysis by Bespoke.Much of that gain has been driven by Apple's quarter-to-date gain of more than 20%.\nYear-to-date, Apple is up 31%, compared to Berkshire Hathaway's return of 26%. Apple's stock price was less than $1.00 away from hitting a $3 trillion valuation on Monday.\nBerkshire's three largest positions after Apple are Bank of America,American Express, and Coca-Cola, which make up a combined 30% of the equity portfolio's value. And Berkshire is still sitting on about $150 billion in cash that it has yet to put to work.","news_type":1,"symbols_score_info":{"AAPL":0.9,"BRK.B":0.9,"BRK.A":0.9}},"isVote":1,"tweetType":1,"viewCount":3154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693778284,"gmtCreate":1640090951437,"gmtModify":1640090951437,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"Wow, just wow","listText":"Wow, just wow","text":"Wow, just wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693778284","repostId":"1148289841","repostType":4,"repost":{"id":"1148289841","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640085374,"share":"https://www.laohu8.com/m/news/1148289841?lang=zh_CN&edition=full","pubTime":"2021-12-21 19:16","market":"us","language":"en","title":"Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148289841","media":"Benzinga","summary":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalm","content":"<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p><p><blockquote><b>阿尔代拉治疗公司</b>报告了reproxalap滴眼液治疗干眼症的3期TRANQUILITY试验的顶线数据。</blockquote></p><p> <ul>  <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>  <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>  <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>  <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>  <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>  <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>  <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>  <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li> </ul> <img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该试验未能达到眼睛发红的主要终点，但在次要终点Schirmer检验的干眼症体征方面确实达到了统计学意义。</li><li>对超过10 mm的Schirmer试验应答者的事后评估也达到了统计学显著性。</li><li>即将进行的3期TRANQUILITY-2试验的主要终点已被修改，如果Schirmer检验或眼部发红显示出统计学显著性，则达到终点。</li><li>此外，TRANQUILITY-2的目标入组已从300名患者增加到最多400名患者。该公司预计营收将于2022年中期公布。</li><li>公司拟于2022年年中提交干眼症适应症的上市申请。</li><li>过敏性结膜炎（另一个拟定适应症）的申请预计将在提交干眼症后和完成FDA要求的额外过敏原室试验后进行。</li><li>未观察到安全性信号，reproxalap耐受性良好；无治疗相关停药或中度或重度不良事件。</li><li><b>价格走势：</b>周二最后一次盘前交易中，ALDX股价下跌38.29%，至4.4美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study<blockquote>Aldeyra的干眼症候选药物在后期研究中令人失望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-21 19:16</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Aldeyra Therapeutics Inc</b>&nbsp;reported topline data&nbsp;from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.</p><p><blockquote><b>阿尔代拉治疗公司</b>报告了reproxalap滴眼液治疗干眼症的3期TRANQUILITY试验的顶线数据。</blockquote></p><p> <ul>  <li>The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.</li>  <li>Statistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.</li>  <li>The primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.</li>  <li>In addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.</li>  <li>The company intends to file the marketing application for dry eye disease indication in mid-2022.</li>  <li>Application for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.</li>  <li>No safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.</li>  <li><b>Price Action:</b>&nbsp;ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.</li> </ul> <img src=\"https://static.tigerbbs.com/b2918c536ca5a074f762901ace4764fc\" tg-width=\"710\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该试验未能达到眼睛发红的主要终点，但在次要终点Schirmer检验的干眼症体征方面确实达到了统计学意义。</li><li>对超过10 mm的Schirmer试验应答者的事后评估也达到了统计学显著性。</li><li>即将进行的3期TRANQUILITY-2试验的主要终点已被修改，如果Schirmer检验或眼部发红显示出统计学显著性，则达到终点。</li><li>此外，TRANQUILITY-2的目标入组已从300名患者增加到最多400名患者。该公司预计营收将于2022年中期公布。</li><li>公司拟于2022年年中提交干眼症适应症的上市申请。</li><li>过敏性结膜炎（另一个拟定适应症）的申请预计将在提交干眼症后和完成FDA要求的额外过敏原室试验后进行。</li><li>未观察到安全性信号，reproxalap耐受性良好；无治疗相关停药或中度或重度不良事件。</li><li><b>价格走势：</b>周二最后一次盘前交易中，ALDX股价下跌38.29%，至4.4美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148289841","content_text":"Aldeyra Therapeutics Inc reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease.\n\nThe trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint.\nStatistical significance was also achieved for the post-hoc assessment of Schirmer test responders of over 10 mm.\nThe primary endpoint of the upcoming Phase 3 TRANQUILITY-2 trial has been modified such that the endpoint will have been met if either the Schirmer test or ocular redness demonstrates statistical significance.\nIn addition, target enrollment in TRANQUILITY-2 has been increased from 300 to up to 400 patients. The company expects topline results in mid-2022.\nThe company intends to file the marketing application for dry eye disease indication in mid-2022.\nApplication for allergic conjunctivitis, another proposed indication, is expected to occur after the dry eye disease submission and following completion of an additional allergen chamber trial requested by the FDA.\nNo safety signals were observed, and reproxalap was well tolerated; there were no treatment-related discontinuations or moderate or severe adverse events.\nPrice Action: ALDX shares are down 38.29% at $4.4 during the premarket session on the last check Tuesday.","news_type":1,"symbols_score_info":{"ALDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691187998,"gmtCreate":1640150149936,"gmtModify":1640150150023,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"I think he needs a new cfo, like like there's no financial planning within the company","listText":"I think he needs a new cfo, like like there's no financial planning within the company","text":"I think he needs a new cfo, like like there's no financial planning within the company","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691187998","repostId":"2193167797","repostType":4,"isVote":1,"tweetType":1,"viewCount":1208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690959006,"gmtCreate":1639624289105,"gmtModify":1639624315784,"author":{"id":"4100142878992660","authorId":"4100142878992660","name":"holybun","avatar":"https://static.tigerbbs.com/8770ac73bdb77d59fbb74bf3e88d1ccd","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100142878992660","idStr":"4100142878992660"},"themes":[],"htmlText":"very nice","listText":"very nice","text":"very nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690959006","repostId":"607944827","repostType":1,"repost":{"id":607944827,"gmtCreate":1639481361363,"gmtModify":1639504322704,"author":{"id":"3527667618821228","authorId":"3527667618821228","name":"MillionaireTiger","avatar":"https://static.tigerbbs.com/8901a3026957857b6996ae953d595bee","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667618821228","idStr":"3527667618821228"},"themes":[],"title":"Pfizer Announced its Acquisition of Arena Pharmaceuticals in a $6.7 Billion","htmlText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","listText":"Hey&nbsp;Tigers! Do&nbsp;you&nbsp;notice&nbsp;Pfizer's&nbsp;new&nbsp;play? Pfizer&nbsp;announced its&nbsp;acquisition&nbsp;of&nbsp;Arena Pharmaceuticals&nbsp;today in a&nbsp;$6.7 billion deal&nbsp;for the company’s research on inflammatory conditions affecting the stomach and intestine.&nbsp;Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly&nbsp;doubled&nbsp;yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","text":"Hey Tigers! Do you notice Pfizer's new play? Pfizer announced its acquisition of Arena Pharmaceuticals today in a $6.7 billion deal for the company’s research on inflammatory conditions affecting the stomach and intestine. Pfizer will pay Arena $100/share in cash. Shares of Arena stock nearly doubled yesterday as the company pursues treatments for ulcerative colitis and Crohn’s disease, as well as other dermatological, gastrointestinal, and cardiac conditions — Arena’s etrasimod drug for ulcerative colitis/Crohn’s is currently in late-stage trials. The acquisition’s timing is no coincidence as Pfizer also investigates treatments for gastrointestinal conditions. Pfizer is on a roll, lately. In addition to the o","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607944827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}